Two more Orion trials have hit neatly and cleanly, and now success will be largely down to pricing.
Hiking the price of a drug before generics appear is a long-enshrined practice, a situation that applies to most of the products singled out by Icer.
Companies and investors have not completely dismissed the UK Labour party’s proposals for cheaper drugs – but some ideas have proven more equal than others.
The long-awaited robotic surgery system is designed to open up the market.
Novo Nordisk says that oral semaglutide’s list price will be “similar” to Ozempic’s, but it will be a while before its true cost becomes apparent.
Roche’s lower price tag for its targeted cancer therapy Rozlytrek could – intentionally or not – hit one of Bayer’s big hopes hard.
The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.
Its gene therapy is three years away from market, but Mustang is already thinking about outcomes-based pricing.
Pfizer opts not to start a price war with Alnylam and Ionis, but could there be a pricing loophole?